Tag Archives: stroke
March 2010 Br J Cardiol 2009;17(Suppl 1):S10-11
Is dual antiplatelet therapy needed for all CVD patients?
Ranil de Silva
Dual antiplatelet therapy for all CVD patients? Table 1. Currently used antiplatelet drugs Currently used antiplatelet drugs are summarised in table 1 and pivotal clinical trials of dual antiplatelet therapy in table 2. The Clopidogrel for High Atherothrombotic Risk and Ischaemia Stabilisation, Management and Avoidance (CHARISMA) trial2 is the only prospective randomised clinical trial to evaluate the efficacy and safety of dual antiplatelet therapy in all CVD patients. Initiated after the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial had shown a 9% relative risk reduction with clopidogrel compared w
November 2009 Br J Cardiol 2009;16:269-71
Increasing treatment window for tPA in stroke
BJCardio editorial staff
This new report from ECASS 3 was published online on October 21st in Lancet Neurology. The authors, led by Dr Werner Hacke (Ruprecht-Karls-Universität, Germany) report that although not all end points were statistically significant, there was “a clear pattern in favour of alteplase”. In the ECASS 3 trial, 821 stroke patients presenting 3-4.5 hours after symptom onset were randomised to alteplase (in the approved regimen of 0.9 mg/kg body weight) or placebo. The primary end point was disability at 90 days, and this was judged by a favourable or unfavourable outcome on the modified Rankin Scale. Results showed that significantly more pati
September 2007 Br J Cardiol 2007;14:190
REACHing for new heights in disease management
Deepak L Bhatt, P Gabriel Steg
In this larger context, the international Reduction of Atherothrombosis for Continued Health (REACH) Registry was launched in order to study outcomes of atherothrombotic disease, risk factors for atherothrombosis, and also current treatment patterns. Already, the REACH Registry has provided insights at a global level.1 For example, under-treatment of common risk factors such as hypertension, hyperlipidaemia, and diabetes was observed in all regions included in the REACH Registry. Obesity, including morbid obesity, was highly prevalent. Multivascular disease – atherothrombosis affecting more than one arterial territory – was present in app
November 2006 Br J Cardiol 2006;13:386-90
News from the Scientific Sessions 2006 of the American Heart Association
BJCardio editorial team
No content available
July 2005 Br J Cardiol 2005;12:308-11
Atrial fibrillation: strategies in primary care
Michael Kirby
No content available
January 2005 Br J Cardiol 2005;12:53-6
Holes and strokes
Mushtaq Wani, Ranjini Navaratnasingam
No content available
November 2004 Br J Cardiol 2004;11:479-82
Carotid artery disease: stenting, endarterectomy or medical therapy?
Mitchell M Lindsay, Keith G Oldroyd
No content available
July 2004 Br J Cardiol 2004;11:315-20
Angiotensin II receptor blockers: a new lease of LIFE?
Michael Kirby, Rubin Minhas
No content available
November 2003 Br J Cardiol 2003;10:478-81
Diabetes and coronary heart disease: combining the National Service Frameworks
Mike Mead
No content available
May 2003 Br J Cardiol 2003;10:197-205
Thrombolytic therapy for acute ischaemic stroke
Matthew Walters, Jacqueline Taylor, Adrian Brady
No content available
For healthcare professionals only
